Development of apricitabine halted without finding backer for Phase 3
1 June 2010. Related: Antiretrovirals.
On 10 May 2010, the Australian biotechnology company Avexa, announced the closure of the development programme for the nucleoside apricitabine (AVX754).
According to an earlier statement in March, initial three-week results from the study suggest activity against HIV with M184V mutation, associated with high-level resistance to 3TC and FTC.
Apricitabine is a cytidine analogue similar to 3TC and 48-week results from Phase 2b studies were presented at the HIV Congress in Glasgoew in 2008. [2]
Avexa were developing apricitabine under license from Shire Pharmaceuticals.
References
1. Avexa Press Statement (10 May 2010).
http://www.avexa.com.au/freestyler/files/Avexa%20closes%20apricitabine%20program.pdf
2. Cahn P et al. 48-week data from Study AVX-201 A randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. 9th International Congress on Drug Therapy in HIV Infection Glasgow, 913 November 2008. Abstract O414.
http://www.springerlink.com/content/j316274167445388/fulltext.pdf